2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2019. Diabetes Care. 2019; 42:S13-S28

Brannick B, Dagogo-Jack S. Prediabetes and Cardiovascular Disease. Endocrinol Metab Clin North Am. 2018; 47:(1)33-50

Buse JB, Wexler DJ, Tsapas A 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2020; 43:(2)487-493

Carlsson LMS, Sjöholm K, Karlsson C Long-term incidence of microvascular disease after bariatric surgery or usual care in patients with obesity, stratified by baseline glycaemic status: a post-hoc analysis of participants from the Swedish Obese Subjects study. Lancet Diabetes Endocrinol. 2017; 5:(4)271-279

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet. 2002; 359:(9323)2072-2077

Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003; 290:(4)486-494

Costa EC, Hay JL, Kehler DS Effects of High-Intensity Interval Training Versus Moderate-Intensity Continuous Training On Blood Pressure in Adults with Pre-to Established Hypertension: A Systematic Review and Meta-Analysis of Randomized Trials. Sports Med. 2018; 48:(9)2127-2142

DeFronzo RA, Tripathy D, Schwenke DC Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med. 2011; 364:(12)1104-1115

The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002; 25:(12)2165-2171

Diabetes UK. Differences between Type 1 and Type 2 Diabetes. 2020. (accessed 19 March 2020)

Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, Khunti K. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care. 2014; 37:(4)922-933

Esposito K, Maiorino MI, Bellastella G, Chiodini P, Panagiotakos D, Giugliano D. A journey into a Mediterranean diet and type 2 diabetes: a systematic review with meta-analyses. BMJ Open. 2015; 10:(8)

Francois ME, Pistawka KJ, Halperin FA, Little JP. Cardiovascular benefits of combined interval training and post-exercise nutrition in type 2 diabetes. J Diabetes Complications. 2018; 32:(2)226-233

Motivational Interviewing Strategies to Facilitate Adolescent Behavior Change Adolescent Health Update. 2007. (accessed 19 March 2020)

Grundy SM. Pre-diabetes, metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2012; 59:(7)635-643

Herings RMC, de Boer A, Leufkens HGM, Porsius A, Stricker BHC. Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme. Lancet. 1995; 345:(8959)1195-1198

Huang PL. A comprehensive definition for metabolic syndrome. Dis Model Mech. 2009; 2:(5-6)231-237

Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016; 355

International Diabetes Federation. IDF Consensus Worldwide Definition of the Metabolic Syndrome. 2006. (accessed 19 March 2020)

Kristensen SL, Preiss D, Jhund PS Risk Related to Pre–Diabetes Mellitus and Diabetes Mellitus in Heart Failure With Reduced Ejection Fraction. Circ Heart Fail. 2016; 9:(1)

le Roux CW, Astrup A, Fujioka K 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial. Lancet. 2017; 389:(10077)1399-1409

Lindström J, Louheranta A, Mannelin M The Finnish Diabetes Prevention Study (DPS): lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care. 2003; 26:(12)3230-3236

MacDonald MR, Petrie MC, Varyani F Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008; 29:(11)1377-1385

Marso SP, Daniels GH, Brown-Frandsen K Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016; 375:(4)311-22

Maki KC, Diwadkar-Navsariwala V, Kramer MW. Statin use and risk for type 2 diabetes: what clinicians should know. Postgrad Med. 2018; 130:(2)166-172

Middelbeek RJW, Abrahamson MJ. Diabetes, prediabetes, and glycemic control in the United States: challenges and opportunities. Ann Intern Med. 2014; 160:(8)572-573

Miller WR, Rose GS. Toward a theory of motivational interviewing. Am Psychol. 2009; 64:(6)527-537

National Institute for Health and Care Excellence. Hypertension in adults: diagnosis and management. 2019. (accessed 19 March 2020)

National Institute for Health and Care Excellence. Obesity: identification, assessment and management. 2014. (accessed 19 March 2020)

National Institute for Health and Care Excellence. Cardiovascular disease: risk assessment and reduction, including lipid modification. 2016. (accessed 19 March 2020)

National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk: glossary. 2017a. (accessed 19 March 2020)

National Institute for Health and Care Excellence. Type 2 diabetes: prevention in people at high risk: metformin. 2017b. (accessed 19 March 2020)

Papa G, Degano C, Iurato MP, Licciardello C, Maiorana R, Finocchiaro C. Macrovascular complication phenotypes in type 2 diabetic patients. Cardiovasc Diabetol. 2013; 12:(1)

Ratner R, Goldberg R, Haffner S, Marcovina S, Orchard T, Fowler S, Temprosa M Impact of intensive lifestyle and metformin therapy on cardiovascular disease risk factors in the diabetes prevention program. Diabetes Care. 2005; 28:(4)888-894

Salpeter SR, Buckley NS, Kahn JA, Salpeter EE. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med. 2008; 121:(2)149-157.e2

Stehouwer CDA. Microvascular Dysfunction and Hyperglycemia: A Vicious Cycle With Widespread Consequences. Diabetes. 2018; 67:(9)1729-1741

Sun Y, You W, Almeida F, Estabrooks P, Davy B. The Effectiveness and Cost of Lifestyle Interventions Including Nutrition Education for Diabetes Prevention: A Systematic Review and Meta-Analysis. J Acad Nutr Diet. 2017; 117:(3)404-421.e36

Tougas ME, Hayden JA, McGrath PJ, Huguet A, Rozario S. A Systematic Review Exploring the Social Cognitive Theory of Self-Regulation as a Framework for Chronic Health Condition Interventions. PLoS One. 2015; 10:(8)

Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation.Geneva: World Health Organization; 2006

Pre-diabetes and cardiovascular risk: detonating the time bomb

02 May 2020
Volume 31 · Issue 5


Pre-diabetes carries a cardiovascular risk. Beverley Bostock-Cox considers the interventions that can improve this risk in people with pre-diabetes

Pre-diabetes is a state of impaired glucose regulation where the body moves from normal levels of blood glucose to a position where increasing levels of insulin resistance result in higher and harmful sugar levels in the bloodstream. As its name suggests, it is a precursor of type 2 diabetes. Cardiovascular risk is also likely to be higher, mainly because of the links between hyperglycaemia and other known cardiovascular risk factors such as hypertension and dyslipidaemia. In people with pre-diabetes, the aim should be to treat all the modifiable risk factors through lifestyle interventions, especially by encouraging weight loss and increasing physical activity levels. Pharmacological interventions can be considered in addition to lifestyle change.

Type 1 diabetes is an autoimmune condition which tends to present acutely, with a swift and catastrophic loss of beta cell function in the pancreas leading to significant hyperglycaemia and, in some cases, potentially life threatening ketoacidosis (Diabetes UK, 2020). There is still a lack of clarity about why people develop type 1 diabetes, and as yet, prevention is not possible. In contrast, type 2 diabetes has a more gradual onset, with research showing that people often move through a process of normal insulin and glycaemic levels, to insulin resistance and hyperinsulinaemia, through to pre-diabetes and then to diabetes, with the potential to develop vascular complications (Stehouwer, 2018). At each stage there is the potential to halt, or at least slow down, the process and improve outcomes, often through lifestyle changes (Dunkley et al, 2014; Sun et al, 2017).

Register now to continue reading

Thank you for visiting Practice Nursing and reading some of our peer-reviewed resources for general practice nurses. To read more, please register today. You’ll enjoy the following great benefits:

What's included

  • Limited access to clinical or professional articles

  • New content and clinical newsletter updates each month